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Summary When the expected effect of an inhaled drug is not achieved, the cause
could be poor inhalation technique and consequently a low pulmonary dose. A simple
in vivo test to evaluate the pulmonary dose would be a benefit. This study evaluates
the relative and systemic bioavailability following inhalation of nebulized sodium
cromoglycate (SCG) in healthy subjects. Blood samples were collected during 240min
and urine was collected in two portions, up to 6 h post-inhalation. Two exposures
were performed and comparisons based on the quantification of drug in plasma and
urine by a high-performance liquid chromatography (HPLC) procedure were done. In
one of the exposures, a pulmonary function test was performed to study if an
expected effect of increased absorption could be detected. There was a good
correlation between the two exposures shown in the plasma concentrations, but not
in the urine analyses. The forced exhaled volume manoeuvres were associated with a
higher Cmax and plasma concentrations up to 60min post-inhalation (Po0:01). This
effect was not detected in the urine analyses. We conclude that this pharmacokinetic
method with inhaled SCG and plasma analyses could be used to evaluate individual
inhalation technique. The HPLC method used was rapid and had adequate sensitivity.
& 2003 Elsevier Ltd. All rights reserved.
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Introduction
Administration of a drug by inhalation is a widely
used and well-accepted therapy today in the
treatment of obstructive respiratory disorders.
The drug is administered by an inhalation device,
e.g. a pressurized metered-dose inhaler, a dry
powder inhaler or a nebulizer. Even with an optimal
inhalation condition only 5–30% of the labelled dose
is deposited in the lung.1–3 The major part is
deposited in the inhalation device and in the mouth
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and throat. The mouth and throat deposition is
highly individual and can in some subpopulations of
asthmatics be extremely high, 470%. As an
individual factor, a pharyngeal configuration, both
functional and/or anatomical, could be the cause.4
There is a general relationship between lung
deposition and pharmacological effect of a drug.5
Hence, it would be a benefit to find a simple
method to measure lung deposition that can be
used for screening purposes to identify if inhalation
aspects are important when the clinical outcome is
not as expected.
The most commonly used methods to assess the
lung deposition in vivo are pharmacokinetic studies
and studies using inhaled radiolabelled particles or
drugs together with gamma scintigraphy techni-
que.6,7 Results from studies using radiolabelled
particles indicate large inter-individual differences
but good reproducibility within subjects.8,9 These
kinds of studies are expensive, need specific
equipment and expertize, and expose the subjects
to radioactivity. The pharmacokinetic methods are
easier to perform, but limited to evaluate only
total lung deposition, based on the quantification
of drug in plasma or urine. The systemic drug level
results from absorption of the inhaled drug via the
respiratory epithelium and/or via the gastrointest-
inal tract (the orally deposited dose and possible
drug metabolism). To be able to estimate the
relative bioavailability of total lung deposition, it is
assumed that the absorbed drug via the g.i tract
can be excluded and that there is no metabolism of
the drug. With the charcoal-block method the
gastrointestinal uptake is blocked by swallowed
charcoal slurry. The inhaled dose of water-soluble
substances, e.g. terbutaline sulphate and budeso-
nide, is calculated from the excreted amount in
urine collected during 48 h post-inhalation.10 The
subjects need to be highly motivated to accept oral
charcoal administration. Furthermore, the subjects
need to be under close observation to control
medication and urine collection during the study.
Another pharmacokinetic method is to measure
plasma salbutamol concentrations during the first
20min post-inhalation11 or the amount of salbuta-
mol excreted in the urine during the first 30min
post-inhalation. This latter method is possible since
the contribution to urinary excretion from the
gastrointestinal tract is negligible during the first
30min and no oral block of the gastrointestinal
absorption is required.12 Aswania and co-workers
reported a method to measure relative bioavail-
ability of inhaled sodium cromoglycate (SCG) in
urine 1 h post-inhalation.13
SCG is a well-known and safe drug, almost free
from side-effects, and it is highly soluble in water.
A very small portion of the drug (approximately 1–
3%) is absorbed by the gastrointestinal tract after
oral administration.14 But after inhalation the drug
is well absorbed by the respiratory epithelium into
the systemic circulation and rapidly eliminated
unchanged in approximately equal proportions in
the urine and the bile.15,16 The plasma concentra-
tion rises rapidly after inhalation and reaches a
peak at about 15min after inhalation, terminal
half-time is 90–150min.17 Since only a minor part is
absorbed from the gastrointestinal tract, the
plasma concentration and urinary excretion of
SCG are indicators of the dose absorbed from the
airways. The plasma concentration can easily be
influenced and increases temporarily after a forced
expiratory manoeuvre due to increased pulmonary
absorption to the systemic circulation.18
For the chemical analysis of SCG in urine, where
the concentration is relatively high, high-perfor-
mance reversed phase liquid chromatography (HPLC)
has been used with an ion-pairing technique.19,20 For
the determination of low concentrations obtained
from plasma samples, immunological methods have
been commonly used.21 After the completion of our
study two alternative methods have appeared. One
procedure comprises liquid–liquid extraction of
plasma and urine samples,22 followed by HPLC with
UV detection, and the second uses a liquid chroma-
tography tandem mass spectrometry (LC-MS-MS)
method after solid phase extraction.23
The aim of the present study was to evaluate a
pharmacokinetic method to be used as a simple
clinical test to estimate the relative bioavailability
in the lung following inhalation of SCG. Two
exposures were performed and measurements in
plasma over time and excreted amounts in urine
were compared. In order to study whether an
expected effect of increased absorption could be
detected both in plasma and urine, the study
protocol included a clinical routine procedure, a
pulmonary function test (PFT) before and after
inhalation at one of the exposures. The study also
evaluated an HPLC procedure of SCG, both in plasma
and urine samples, for routine purposes. The HPLC
procedure comprised solid phase extraction of the
drug, followed by reverse phase chromatography,
using dodecyl triethyl ammonium ion as a counterion.
Materials and methods
Subjects and inhalation
Eleven healthy non-smoking volunteers (four
males, one former smoker) aged 24.673.3 years,
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with no history of asthma took part in the study.
The number of study subjects were chosen to be
able to detect an average of plasma concentration
that could be considered relevant, i.e. about 30%
increase from average. No subject was on regular
medication except anticonceptions and no one had
any current upper respiratory tract infection or had
taken any antibiotics during the two previous
months. The study was approved by the Ethics
Committee on Human research at Huddinge Uni-
versity Hospital in Stockholm and all subjects gave
their informed consent. The subjects had a light
breakfast in the morning of the test days.
The study was an open randomized study with a
washout time between the two exposures of at
least 48 h. The exposure set-up consisted of a
nebulizer (Pari inhalierboy LC, Pari-Werk, GmbH,
Germany), a Pari exhalation filter and a filter pad
(Paria GmbH, Germany). The nebulizer was filled
with 2ml SCG solution (10mg/ml). The subjects
inhaled in a sitting position through a mouthpiece,
wearing a nose clip. Each subject made 27 deep
inhalations within 3min, at a preset flow of 0.5 l/s,
and the subjects exhaled through a filter. The
nebulizer was connected to a dosimeter (Spira
Electro 2, Spira Health Care, Finland) that was
preset with a nebulization delay of 20ml of inspired
air prior to the onset of the nebulization, and a
nebulization period of 1.5 s. The mass median
aerodynamic diameter (MMAD) of the aerosol was
7.7 mm measured with a light-scattering instrument
(Malvern Mastersizer, Malvern, UK). The output
from the nebulizer was 7 ml solution/s, and the
available dose to the subject was calculated to be
2.8mg. In a separate measurement, the actual
available dose was determined by analysing neb-
ulized SCG on filters with the same set-up as used in
the exposures. At one of the exposures a routine
intervention was included, containing a PFT (Vita-
lograph Ltd., Buckingham, UK) measuring forced
vital capacity and forced exhaled volume in 1 s
(FEV1) before inhalation and 20min post-inhala-
tion. SCG on filters was assayed, after extraction
with ethanol/water 1/1, using a reverse phase LC
method.24
Blood Sampling
A 5ml venous blood sample was taken via an
indwelling antecubital cannula (Venflon; Ohmeda
AB, Helsingborg, Sweden) prior to inhalation and
15, 30, 60, 120 and 240min post-inhalation. The
first 1ml of blood from each sample was discarded
and, after collection, the cannula was flushed with
3ml saline (9mg/ml). The blood was drawn into
glass tubes containing sodium fluoride heparin. The
plasma was separated by centrifugation, stored in
polystyrene tubes, and immediately frozen at
401C until analysed. Before the start of the two
exposures, the subjects were instructed to com-
pletely empty their urine bladder and 20ml urine
was taken as a baseline sample. Urine was
collected in two portions, 0–3 and 3–6 h post-
inhalation. The volume of each urine portion was
measured and 20ml urine was taken from each
portion, stored in polystyrene tubes, and immedi-
ately frozen at 401C until analysed.
The HPLC procedure
Cromoclycate disodium salt and benzalconium
chlorides were obtained from Sigma Chemicals
Co. (St. Louis, MO, USA). Acetonitrile was of
HPLC-grade and all other chemicals of pro-analysis
quality. SepPak Light C18 cartridges were obtained
from Waters Inc. (Milford, MA, USA). BondELUT 1cc
SPE syringe type cartridges (Analytichem Interna-
tional, Harbor City, USA), cut to 5mm length and
emptied, were used together with Gilson sealing
caps for sealing of SepPak inlets. The chromato-
graphy equipment consisted of a model 2150 HPLC
pump (Amersham-Pharmacia AB, Uppsala, Swe-
den), a Gilson Aspec sample preparation system
(Gilson SA, Villiers-le-Bel, France), modified for
SepPak light cartridges and equipped with a 5ml
dispenser syringe and a 2ml loop. A Zorbax SB C18
column (Agilent Technologies Inc, Newport, DE,
USA), 75 4.6mm and with 3 mm particles, was
used for separation and a Spectromonitor 3200
variable wavelength monitor for detection. A
Shimadzu C-R5A integrator (Shimadzu AG, Duis-
burg, Germany) was used for recording the signal.
The eluent was a 10mM acetic acid, 5mM ammonia
buffer (pH¼ 4.7), containing 6mM benzalconium
chloride and 48% of acetonitrile. Eluent flow was
1.5ml/min and the chromatography was run at
ambient temperature and monitored at 326 nm.
The Gilson Aspec apparatus was programmed to
process the samples according to the following
procedure:
1. SepPak cartridges were pre-treated with 1ml of
methanol followed by 1ml of 5% methanol in
water.
2. Plasma, 1ml, or urine, 1ml, which was diluted
10 times, was mixed with 0.5ml of 3.85M
phosphoric acid and 1.45ml of the mixture was
passed through the SepPak cartridge at a flow
rate of 0.75ml/min.
3. Each cartridge was washed with 4.0ml of 15%
acetonitrile in 40mM hydrochloric acid at a flow
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rate of 1.5ml/min, followed by 180 ml of 15%
acetonitrile in 20mM acetic acid and 15mM
ammonia (pH 5.0) at a flow rate of 0.75ml/min.
4. SCG was eluted with 600 ml of 15% acetonitrile in
20mM acetate buffer (pH 5.0) at a flow rate of
0.75ml/min.
5. Five hundred microlitres of the eluent was
injected automatically in the chromatograph.
Total cycle time of the procedure was 10min.
Statistical analysis and AUC evaluation
In the subject study we compared different
estimates of relative bioavailability in the lung
following inhalation of SCG, the peak values of SCG
(Cmax), the sum of the first three plasma concen-
trations after exposure and the area under the
curve (AUC). The AUC (time 0–240min) was
calculated by the trapezoidal rule, C0 was set to
zero. The total amount excreted SCG in urine
(Urinedose) was calculated by multiplying the
concentration in urine with measured volume.
The bioavailability in percentage of inhaled dose
was calculated by the formula (assuming that
excretion by urinary tract is 50%): Urinedose 2/
(Inhaleddose) 100. The results are presented as
mean7SD. Data were analysed statistically by using
the Pearson correlation coefficient for parametric
samples, the Wilcoxon signed ranks test for
differences between the two exposures and linear
regression of least squares were calculated.
Results
Subjects results
The FEV1 of all subjects was greater than 85% of the
predicted value. There was no difference in FEV1
before (3.870.9 l) or after (3.770.9 l) the inhala-
tion of SCG.
The mean dose delivered to the subjects,
measured on filter, was 2.6mg or 93% of calculated
output dose from the nebulizer. This measured
filter dose was used in the calculation as the
available inhaled dose to the subject. The exhaled
amounts of SCG measured on filter in the base
exposure were 72718 and 57723 mg (mean7SD) in
the exposure with the PFT and these amounts
correspond to 2.8% and 2.2% of the available dose,
respectively, indicating an almost complete subject
deposition. None of the baseline samples in blood
or urine showed any trace of SCG.
The individual data of the plasma concentrations
are shown in Table 1. The Cmax was 9.674.1 and
13.474.5 ng/ml in the two exposures, respectively.
The Cmax was highest at mean 30min after
inhalation. In the base exposure two subjects had
the Cmax at 15min, and in the exposure with the
PFT three had Cmax at 60min post-inhalation. The
mean plasma concentrations and AUC in the two
different exposures are shown in Table 2. Overall
increased plasma concentrations were found, ex-
cept for the last measured plasma concentration at
240min post-inhalation, in the exposure with the
PFT. The mean plasma concentration curves from
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Table 1 Individual data on plasma concentrations (ng/ml) after a nebulised solution of SCG at each measure
point in the base exposure and in the exposure with a pulmonary function test (PFT).
Subj No. Time (min) Cmax AUC
15 30 60 120 240 (ng/ml) (mg/min/ml)
Base PFT Base PFT Base PFT Base PFT Base PFT Base PFT Base PFT
1 9.1 13.9 8.4 15.1 9.9 11.6 7.7 8.1 6.3 4.0 9.9 15.1 1.85 2.04
2 8.4 9.2 11.4 13.9 9.1 9.8 6.9 8.1 5.2 5.2 11.4 13.9 1.73 1.95
3 5.4 7.5 5.4 11.7 5.4 11.2 4.2 11.5 3.1 5.7 5.4 11.7 1.01 2.25
4 3.2 5.2 3.9 6.3 3.9 5.7 3.6 5.2 3.1 4.2 3.9 6.3 0.82 1.19
5 9.9 8.6 10.6 12.7 8.4 9.2 5.4 6.3 4.5 6.9 10.6 12.7 1.52 1.80
6 8.3 12.1 6.8 13.3 7.7 7.5 6.1 5.2 4.5 2.4 8.3 13.3 1.45 1.43
7 11.1 12.7 18.1 20.3 15.7 22.6 12.5 8.4 6.1 2.4 18.1 22.6 2.76 2.55
8 6.1 8.1 6.1 8.1 7.7 9.1 6.1 5.4 3.7 3.9 7.7 9.1 1.36 1.45
9 6.1 7.7 6.1 15.6 6.1 12.7 5.3 8.6 4.5 4.7 6.1 15.6 1.26 2.15
10 10.1 6.9 8.5 7.7 9.3 9.1 7.7 7.7 6.1 3.9 10.1 9.1 1.82 1.59
11 12.5 13.9 14.1 18.0 6.9 9.9 9.3 9.1 5.3 3.9 14.1 18.0 1.98 2.11
Mean 8.2 9.6 9.0 13.0 8.2 10.8 6.8 7.6 4.8 4.3 9.6 13.4 1.60 1.86
SD 2.8 3.0 4.2 4.4 3.1 4.4 2.5 1.9 1.2 1.3 4.1 4.5 0.53 0.41
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the two exposures are shown in Fig. 1. The Cmax and
the plasma concentration 60min post-inhalation
were significantly higher in the exposure with the
PFT (Po0:01). All except one subject showed
elevated Cmax in the exposure with the PFT
(Fig. 2). There was a good correlation of the sum
of the first three plasma concentrations (C1560),
rp ¼ 0:80; Po0:01; in spite of the difference from
the PFT (Table 2 and Fig. 3). Table 3 shows the
excreted amount of SCG in urine and the excretion
rate, during the two sampling periods, following
the two different exposures. Subject no. 10 was
excluded in the results of the urine analyses
because of failure to complete the urine collection.
The total lung deposition in percentage of the
delivered dose was 66% (50; 82, 95% CI) and 53%
(36; 71, 95% CI) in the base exposure and the
exposure with the PFT, respectively, calculated
from excreted amount in urine during 6 h. This high
recovery found depended on the estimation from
the delivered dose to the subject and not the
nominal/labelled dose as usually presented in other
studies. The correlation was poor between urine
analyses in the two exposures, rpo0:41 (Table 3
and Fig. 4). No difference between the two
exposures was shown in the calculated AUC, in
the mean excreted amount of SCG in the urine
sampling periods and 0–3 h excretion rate. How-
ever, a tendency for difference with lower excre-
tion rate in the 3–6 h sampling period in the
exposure with the PFT was seen.
The HPLC procedure
Calibration curves were run on 3 consecutive days
and comprised 1–160 ng/ml for serum samples and
0.1–10 mg/ml for urine samples and were calculated
by linear regression. Controls were run in penta-
plicates each day at 5.0 and 50 ng/ml for plasma
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Table 2 Mean (SD) plasma concentrations and AUC in 11 subjects after a nebulised solution of SCG in two
different exposures, one base exposure and one with a pulmonary function test (PFT) before and 20min post
inhalation. The correlation coefficient between the two exposures was compared.
Base exposure Exposure with PFT Correlation
coefficient, r
Cmax (ng/ml) 9.6 (4.1) 13.4 (4.5)* 0.79**
C15 (ng/ml) 8.2 (2.8) 9.6 (3.0) 0.70
C15–60 (ng/ml) 25.4 (9.3) 33.4 (10.3)* 0.80**
AUC0–240 (mg/min/ml) 1.60 (0.53) 1.86(0.41) 0.58
Cmax; peak plasma concentration; C15, plasma concentration at 15min post inhalation; C1560, the first three plasma
concentrations summarised. *Po0:01; compared data between the two exposures (two-tailed). **Correlation coefficient was
significant, Po0:001:
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samples and at 0.70 and 5.75 mg/ml for urine
samples. Inter- and intra-day precision and accu-
racy were calculated from control values. Detec-
tion limit was defined as values calculated from
three times background noise. Regression coeffi-
cients obtained in calibration curves were better
than 0.99. Based on back-calculation of calibrator
values and coefficients of variation, the low limit of
quantitation (LOQ) for SCG was calculated to 1 ng/
ml in serum and 100 ng/ml in urine. However, it was
shown that 10 ng/ml of SCG could easily be
quantitated in urine by introducing lower calibra-
tors, but this sensitivity was not needed in actual
patient urine samples. Intra-assay precision was
found to be 6.8% at 5.0 ng/ml plasma and 2.5% at
50 ng/ml plasma. The corresponding values for
urine samples were 8.5% at 100 ng/ml and 5.9% at
6000 ng/ml. Inter-assay precision was found to be
4.3% for plasma controls and 4.8% for controls
prepared in urine. Accuracy was calculated to be
11% for plasma controls and 9.3% for urine controls.
The limit of detection (LOD) was calculated to
0.3 ng/ml for plasma samples and 3 ng/ml for urine
samples.
Discussion
The subjects study
In this study, we estimated the relative and
systemic bioavailability to the lungs following
inhalation of nebulized SCG by comparing plasma
concentrations and excreted amount in urine. The
Cmax and the time for the peak to be reached
(30min post-inhalation) are in agreement with
other studies.22,25 Our results show that there was
a larger individual correlation between the two
exposures for the plasma concentrations, r40:6;
than for the urine analysis, ro0:4: The best
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Table 3 Mean (SD) amount excreted (mg) in urine and excretion rate (mg h1) of SCG in 10 subjects following a
nebulised solution of SCG in two different exposures, one base exposure and one with a pulmonary function test
(PFT) before and 20min post-inhalation.
Time intervals Base exposure Exposure with PFT Correlation
coefficient, r
0–3 h excreted SCG (mg) 489 (217) 528 (303) 0.41
3–6 h excreted SCG (mg) 381 (286) 176 (112) 0.08
0–3 h excretion rate (mg/h) 163 (72) 176 (101) 0.41
3–6 h excretion rate (mg/h) 127 (95) 58 (37) 0.08
The correlation coefficient between the two exposures was compared.
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correlation was seen between the first three
summarized plasma concentrations. Several inves-
tigators have shown a wide inter-subject variation
as well as intra-subject variation in plasma con-
centrations.26,27 One reason for this variability
could be variation in the available inhaled dose
from the nominal dose and consequently variation
in the absorbed pulmonary dose. In our study the
subjects inhaled a standardized dose, with a
dosimeter, of nebulized solution of SCG, which
gives a better control of the available dose for
inhalation, and, probably contributed to better
correlation in the plasma concentrations. However,
the same good individual correlation would have
been expected in the AUC and the urine analyses,
at least between the first collected portion, but
that was not seen. With increasing time of
observation, the intra-subject variability increases.
An oral uptake following 1 h post-inhalation could
contribute to poorer individual correlation in AUC
and excreted amount in urine.13 Also, in the early
study by Moss et al., a large variation in excreted
amount of SCG was shown in urine both intra-
individually and inter-individually.15 The absolute
oral bioavailability of SCG in a rat model is
estimated to be 5%.28 However, in human subjects
the oral bioavailability of an oral dose SCG does not
exceed 0.5%.13 The poor correlation between the
urinary samples could also be due to contamination
or incomplete urine collection at each time. This
might be a problem in clinical practice. A better
correlation in urine analyses would probably have
been found if we used more controlled and shorter
collection periods. This would probably demand the
use of urinary catheter. In patients with liver or
kidney disease or medication that affect the bile
pathway or renal function, the assumption that 50%
of the absorbed dose is eliminated through the
renal pathway, can probably not be made. Also, an
intravenous reference dose of SCG to estimate
individual recovery in urine could improve the
individual total bioavailability in urine of an inhaled
SCG dose. But when evaluating inhalation techni-
que within the same subject, this is not needed as
long as the repeated protocol is properly standar-
dized.
The influence of the PFT was seen in the plasma
concentrations but could not be detected in the
urine analysis. The mechanism of increased airway
(epithelial) passage is not fully understood, but it
could be due to mechanical distortion, ‘‘stretch-
ing’’ of the epithelium, in the lungs, drug displace-
ment to a more distal absorption site, or through
increasing lung volume that accelerate drug
absorption in the lung.29 Since the pulmonary
absorption is the rate limiting step, rather than
the elimination rate from systemic circulation,17,30
a difference of excreted amount would have been
expected also in the urine analyses, especially in
the first sampling period, but this was not found in
the present study. However, a slightly increased 0–
3 h elimination rate and a decreased 3–6 h elimina-
tion rate were seen in the exposure with the PFT. A
higher plasma concentration at 15min post-inhala-
tion (before the second FEV1 manoeuvre) in the
exposure with the PFT was probably influenced by
the first FEV1 manoeuvre pre-inhalation. Richards
et al. showed that plasma concentration increases
within 4min after an FEV1 manoeuvre. The plasma
concentrations then declined to the predicted
baseline within 30–60min.18
Using SCG as the inhaled drug gives a simple
method where the test period can be relatively
short (within 4 h) and, the inhaled drug is free from
adverse side-effects. No washout period is usually
needed, since the patients have other medication
than SCG to control their asthma. The limitation of
the method is that the delivered dose given to the
subject should not be lower than 2mg, otherwise
the plasma concentration at 4 h would be below
LOD. Plasma concentrations of SCG are much lower
than the corresponding urine concentrations and
methods with sensitivity down to 1 ng/ml are
needed in order to monitor concentrations after
an inhaled therapeutic dose. The HPLC method
used fulfils all the requirements for a rapid and
convenient method for routine determination of
SCG, both in urine and plasma. The procedure has
shown to be fully automated and more than 50
samples per day can easily be processed, using
Aspec solid-phase extraction, followed by reverse
phase ion-pair chromatography. Validation of the
method has been performed according to standards
and the procedure has been used to assay plasma
and urine concentrations in the present investiga-
tion.
We concluded that plasma sampling is probably
simpler to supervise, the time of the samples can
be more exact and gives a better estimate of
changes in relative bioavailability to the lung
following inhalation. For biofeedback purposes,
the most important aspect is to detect relative
changes from repeated tests within one individual.
As a simple clinical test, to estimate how a patient
inhales, an inhalation test with SCG analysing the
summary of plasma concentrations at 15, 30 and
60min (C1560) could be used for feedback in
inhalation training programmes. When a patient’s
inhalation technique is evaluated with SCG, it is
wise to standardize individually whether a PFT
should be performed or not since it influences the
plasma concentrations and will distort the effect
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evaluation. In studies with children, plasma sam-
pling is also preferred since we think it is easier to
control than urinary excretion. Urinary excretion
on the other hand gives an estimate of total amount
absorbed and might be better for comparison
between individuals but are less useful in compar-
ison within the same subject.
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